Technology Offerings

Innovative AhR Antagonists Target Kynurenin-Producing Tumors

Activation of the aryl hydrocarbon receptor (AHR) by environmental xenobiotic toxins has been implicated in a variety of cellular processes such as embryogenesis, transformation, tumorigenesis and inflammation. The TDO-AHR pathway is active in human brain tumors and associated with malignant progression and poor survival. As Kyn is produced during cancer progression and inflammation in the local microenvironment in amounts sufficient for activating the human AHR, these results can be used to develop a specific chemotherapy to manipulate AhR activated signal pathways in susceptible cancer cells. Using this mechanism more treatment opportunities can be used and different tumor types can be treated by AhR related drugs.

Further Information: PDF

Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Comments (0)

Write a comment